Wet AMD might furthermore be treated with AAV8-associated gene therapy, such as RGX-314 from REGENXBIO Inc. A monoclonal antibody fragment produced by RGX-314 resembles ranibizumab, a well-known anti-VEGF medication. The gene discussed is VEGFA; the disease is age-related macular degeneration.